On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Sigyn Therapeutics Inc. (SIGY) CEO Discusses Company’s Blood Purification Therapies to Address Cancer and Other Life-Threatening Conditions at the Emerging Growth Conference

  • Sigyn Therapeutics CEO Jim Joyce reviewed the company’s pipeline of technologies, including ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM) to improve patient responses to various cancer therapies, and Sigyn Therapy(TM) to address drug resistant viral and bacterial infections, endotoxemia, and sepsis, a leading cause of hospital deaths in the United States
  • The company created Sigyn Therapy(TM) to treat pathogen-associated disorders that are not addressed with drug therapies
  • Sigyn Therapeutics is developing ChemoPrep(TM) and ImmunePrep(TM), to improve patient responses to chemotherapy and immunotherapeutic antibodies, respectively
  • To reduce toxicity, the company designed ChemoPure(TM) to sweep off-target chemotherapy from the bloodstream before it is able to cause the death of healthy patient cells

Sigyn Therapeutics (OTCQB: SIGY), a San Diego-headquartered medical technology company that creates medical solutions to treat life-threatening conditions, took part in the recent Emerging Growth Conference, with CEO Jim Joyce giving a live online presentation and updating attendees on the company’s portfolio of technologies, including Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM), which have each been designed to overcome a current limitation in healthcare (https://ibn.fm/HSNBl).

“We have two classes of product candidates. The first are devices to treat pathogen-associated disorders that are beyond the reach of drugs, and then we have a series of devices designed to improve patient responses to cancer therapies. The convergence of medical devices to enhance cancer drug therapies has the potential to be a new product category,” introduced Mr. Joyce.

Sigyn Therapy(TM)

As it relates to pathogen-associated disorders, the company has advanced Sigyn Therapy(TM) from concept through product development and subsequently completed five invitro blood purification studies, which validated the ability of Sigyn Therapy(TM) to extract 12 different therapeutic targets from human blood plasma.  As a result of these study outcomes, Sigyn Therapy(TM) is a candidate to treat a wide range of pathogen-associated disorders that are not addressed with drug therapies. The company also completed animal studies at the University of Michigan and then collaborated with a leading dialysis organization to establish the treatment protocol, site locations, and principal investigators for first-in-human studies of Sigyn Therapy(TM).

As indicated by Mr. Joyce, “We believe Sigyn Therapy has an unprecedented capability to simultaneously clear deadly inflammatory mediators and pathogenic sources of life-threatening inflammation from human blood.”

Sigyn Therapeutics is preparing to initiate first in-human studies of Sigyn Therapy, having drafted an Investigational Device Exemption (“IDE”) for submission to the U.S. Food and Drug Administration (“FDA”). The study intends to demonstrate the safety of Sigyn Therapy(TM) in dialysis-dependent end-stage renal disease (“ESRD”) patients with endotoxemia and concurrent inflammation. “As per our protocol, we plan to enroll a total of 12 to 15 ESRD patients at three site locations,” he conveyed.

Mr. Joyce went on to discuss the potential value of Sigyn Therapy to the dialysis industry as well as non-dialysis markets. Designed as a single-use disposable device that is deployable on dialysis machines, Sigyn Therapy could provide dialysis organizations such as Fresenius Medical Care and DaVita Inc., a strategy to improve the health of their current patient population as well as a potential pathway into non-dialysis markets.

Solutions to Improve Patient Response to Cancer Therapies

Sigyn Therapeutics is also developing devices to improve patient responses to chemotherapy and immunotherapeutic antibodies to treat cancer.

“Something you need to know – something you probably don’t know – is that both chemotherapy and immunotherapeutic antibodies are poorly delivered to their intended cancer targets,” explained Mr. Joyce. “In general, published reports would indicate that less than 2% of chemotherapy and immunotherapeutic antibodies are successfully delivered to their targets. So, consider that no more than $200 of a $10,000 drug dose is likely to provide patient benefit.  We are looking to overcome the delivery limitations of these drugs.”

Against this backdrop, Sigyn Therapeutics is focused on enhancing the performance of cancer drugs. “We have designed devices to optimize the delivery of chemotherapy and therapeutic antibodies. And we do this by extracting circulating decoys that sequester or interfere with the delivery of these drugs to intended cancer targets. Our clinical objective is straightforward: improve drug delivery, reduce toxicity, and extend patient life,” he continued.

The company has developed ChemoPrep and ImmunePrep, which are designed to enhance the delivery of chemotherapy and therapeutic antibodies, respectively. “ChemoPrep is administered prior to chemotherapy infusion to sweep tumor-derived exosomes and other drug blocking agents from the bloodstream prior to the subsequent administration of chemotherapy.”

To reduce toxicity, the company is developing ChemoPure to be administered after the delivery of chemotherapy to sweep off-target chemotherapy from the bloodstream before it is able to cause the death of healthy patient cells.

In discussing ImmunePrep, Mr. Joyce overviewed the immense opportunities in the therapeutics antibodies market, noting that immunotherapeutic antibodies represent nine of the top 15 selling cancer drugs and have been at the center of multi-billion-dollar mergers and acquisitions. “When we reference immunotherapeutic antibodies, I just want you to know this is inclusive of monoclonal antibodies, checkpoint inhibitors, and antibody drug conjugates. There are over 1000 antibodies right now being evaluated in human studies. However, there is no therapy that’s been proposed prior to ImmunePrep to address the drug decoys that inhibit the delivery of these drugs,” he continued.

Unlike ChemoPrep, ImmunePrep establishes a platform for therapeutic antibodies to be incorporated within medical devices to sweep drug decoys from the bloodstream that would intercept the delivery of the same therapeutic antibody when subsequently administered. The company believes this reverse decoy mechanism will increase the availability of infused antibodies to bind their intended therapeutic target.  Simultaneously, the ImmunePrep device is designed to extract intended cancer cells targets of the antibody from the bloodstream to provide further benefit without added drug toxicity.

Mr. Joyce also fielded questions, using this opportunity to compare the Sigyn Therapy with other blood purification technologies that treat pathogen-associated conditions as well as discuss the company’s potential revenue verticals, funding outlook, development timelines, and potential opportunities to collaborate with medical device and biopharmaceutical organizations.

To listen to the full presentation, please visit https://ibn.fm/7AuwX.

For more information, visit the company’s website at www.SigynTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://ibn.fm/SIGY

About QualityStocks

QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer

QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Archives

Select A Month
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered